| 标题 |
Safety analysis by treatment periods from EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization with durvalumab with/without bevacizumab in participants with embolization-eligible unresectable hepatocellular carcinoma |
| 网址 | |
| DOI | |
| 其它 |
期刊:Journal of Clinical Oncology 作者:Stephen Lam Chan; Bruno Sangro; Masatoshi Kudo; Joseph P. Erinjeri; Shukui Qin; et al 出版日期:2024-06-01 |
| 求助人 | |
| 下载 |
PDF的下载单位、IP信息已删除
(2025-6-4)